101 related articles for article (PubMed ID: 29301826)
1. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Hardwick NR; Frankel P; Ruel C; Kilpatrick J; Tsai W; Kos F; Kaltcheva T; Leong L; Morgan R; Chung V; Tinsley R; Eng M; Wilczynski S; Ellenhorn JDI; Diamond DJ; Cristea M
Clin Cancer Res; 2018 Mar; 24(6):1315-1325. PubMed ID: 29301826
[TBL] [Abstract][Full Text] [Related]
2. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract][Full Text] [Related]
3. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
[TBL] [Abstract][Full Text] [Related]
4. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer.
Yang L; Wang B; Qin J; Zhou H; Majumdar APN; Peng F
Immunopharmacol Immunotoxicol; 2018 Feb; 40(1):91-97. PubMed ID: 29303012
[TBL] [Abstract][Full Text] [Related]
5. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
Chung V; Kos FJ; Hardwick N; Yuan Y; Chao J; Li D; Waisman J; Li M; Zurcher K; Frankel P; Diamond DJ
Clin Transl Oncol; 2019 Mar; 21(3):363-372. PubMed ID: 30094792
[TBL] [Abstract][Full Text] [Related]
7. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B; Yang P; Zhang S
Cancer Commun (Lond); 2024 Mar; 44(3):297-360. PubMed ID: 38311377
[TBL] [Abstract][Full Text] [Related]
8. TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress.
Zhu KL; Su F; Yang JR; Xiao RW; Wu RY; Cao MY; Ling XL; Zhang T
Mol Biol Rep; 2024 Jan; 51(1):205. PubMed ID: 38270700
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X; Yu T; Li X; Zhang N; Foster LJ; Peng C; Huang W; He G
Signal Transduct Target Ther; 2023 Sep; 8(1):335. PubMed ID: 37669923
[TBL] [Abstract][Full Text] [Related]
10. p53 mutation and deletion contribute to tumor immune evasion.
Liu S; Liu T; Jiang J; Guo H; Yang R
Front Genet; 2023; 14():1088455. PubMed ID: 36891151
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic Approaches in Ovarian Cancer.
Yoon H; Kim A; Jang H
Curr Issues Mol Biol; 2023 Feb; 45(2):1233-1249. PubMed ID: 36826026
[TBL] [Abstract][Full Text] [Related]
12. Role of myeloid-derived suppressor cells in tumor recurrence.
Cole K; Al-Kadhimi Z; Talmadge JE
Cancer Metastasis Rev; 2023 Mar; 42(1):113-142. PubMed ID: 36640224
[TBL] [Abstract][Full Text] [Related]
13. GOF Mutant p53 in Cancers: A Therapeutic Challenge.
Dolma L; Muller PAJ
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291874
[No Abstract] [Full Text] [Related]
14. Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed.
Hu X; Bian C; Zhao X; Yi T
Front Immunol; 2022; 13():1034903. PubMed ID: 36275669
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccines: the next immunotherapy frontier.
Lin MJ; Svensson-Arvelund J; Lubitz GS; Marabelle A; Melero I; Brown BD; Brody JD
Nat Cancer; 2022 Aug; 3(8):911-926. PubMed ID: 35999309
[TBL] [Abstract][Full Text] [Related]
16. (Im)maturity in Tumor Ecosystem.
Mortezaee K; Majidpoor J
Front Oncol; 2021; 11():813897. PubMed ID: 35145911
[TBL] [Abstract][Full Text] [Related]
17. Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.
Johnson RL; Cummings M; Thangavelu A; Theophilou G; de Jong D; Orsi NM
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944851
[TBL] [Abstract][Full Text] [Related]
18. In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines.
Lőrincz O; Tóth J; Molnár L; Miklós I; Pántya K; Megyesi M; Somogyi E; Csiszovszki Z; Tőke ER
Cells; 2021 Nov; 10(11):. PubMed ID: 34831269
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Immunological Effects of p53-Targeting Vaccines.
Zhou S; Fan C; Zeng Z; Young KH; Li Y
Front Cell Dev Biol; 2021; 9():762796. PubMed ID: 34805170
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
